S&P 500   4,229.45
DOW   33,002.38
QQQ   354.92
International Paper's 5% Yield Offers Big Value
AI Stock Caught Trading Under Secret Name (Ad)
Warren Buffett's company dumps another 5 million shares of printer maker HP
How You Can Beat the Yields on near 5% Treasuries, plus Upside
AI Stock Caught Trading Under Secret Name (Ad)
5 Economic Trends That Will Drive The Market In Q4
Stock market today: World shares are mostly lower, tracking a rates-driven tumble on Wall Street
Elon Did It Again: This Could be Bigger than Tesla (Ad)
South Asia is expected to grow by nearly 6% this year, making it the world's fastest-growing region
Inflation is Why a Soft Landing is Bad for the Economy
S&P 500   4,229.45
DOW   33,002.38
QQQ   354.92
International Paper's 5% Yield Offers Big Value
AI Stock Caught Trading Under Secret Name (Ad)
Warren Buffett's company dumps another 5 million shares of printer maker HP
How You Can Beat the Yields on near 5% Treasuries, plus Upside
AI Stock Caught Trading Under Secret Name (Ad)
5 Economic Trends That Will Drive The Market In Q4
Stock market today: World shares are mostly lower, tracking a rates-driven tumble on Wall Street
Elon Did It Again: This Could be Bigger than Tesla (Ad)
South Asia is expected to grow by nearly 6% this year, making it the world's fastest-growing region
Inflation is Why a Soft Landing is Bad for the Economy
S&P 500   4,229.45
DOW   33,002.38
QQQ   354.92
International Paper's 5% Yield Offers Big Value
AI Stock Caught Trading Under Secret Name (Ad)
Warren Buffett's company dumps another 5 million shares of printer maker HP
How You Can Beat the Yields on near 5% Treasuries, plus Upside
AI Stock Caught Trading Under Secret Name (Ad)
5 Economic Trends That Will Drive The Market In Q4
Stock market today: World shares are mostly lower, tracking a rates-driven tumble on Wall Street
Elon Did It Again: This Could be Bigger than Tesla (Ad)
South Asia is expected to grow by nearly 6% this year, making it the world's fastest-growing region
Inflation is Why a Soft Landing is Bad for the Economy
S&P 500   4,229.45
DOW   33,002.38
QQQ   354.92
International Paper's 5% Yield Offers Big Value
AI Stock Caught Trading Under Secret Name (Ad)
Warren Buffett's company dumps another 5 million shares of printer maker HP
How You Can Beat the Yields on near 5% Treasuries, plus Upside
AI Stock Caught Trading Under Secret Name (Ad)
5 Economic Trends That Will Drive The Market In Q4
Stock market today: World shares are mostly lower, tracking a rates-driven tumble on Wall Street
Elon Did It Again: This Could be Bigger than Tesla (Ad)
South Asia is expected to grow by nearly 6% this year, making it the world's fastest-growing region
Inflation is Why a Soft Landing is Bad for the Economy
NASDAQ:GTHX

G1 Therapeutics (GTHX) Stock Forecast, Price & News

$1.26
-0.10 (-7.35%)
(As of 10/3/2023 ET)
Compare
Today's Range
$1.24
$1.34
50-Day Range
$1.22
$2.40
52-Week Range
$1.17
$13.85
Volume
550,731 shs
Average Volume
441,309 shs
Market Capitalization
$65.21 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$11.80

G1 Therapeutics MarketRank™ Forecast

Analyst Rating
Moderate Buy
2.83 Rating Score
Upside/​Downside
836.5% Upside
$11.80 Price Target
Short Interest
Healthy
5.60% of Shares Sold Short
Dividend Strength
N/A
Sustainability
-2.45
Upright™ Environmental Score
News Sentiment
N/A
Insider Trading
Selling Shares
$10,866 Sold Last Quarter
Proj. Earnings Growth
Growing
From ($0.92) to ($0.89) Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.09 out of 5 stars

Medical Sector

313th out of 966 stocks

Pharmaceutical Preparations Industry

119th out of 432 stocks


GTHX stock logo

About G1 Therapeutics (NASDAQ:GTHX) Stock

G1 Therapeutics, Inc., a commercial-stage biopharmaceutical company, engages in the discovery, development, and commercialization of small molecule therapeutics for the treatment of patients with cancer. The company offers COSELA, which helps to decrease chemotherapy-induced myelosuppression in adult patients when administered prior to a platinum/etoposide-containing regimen or topotecan-containing regimen for extensive stage small cell lung cancer. It is also developing trilaciclib, a (CDK) 4/6 inhibitor can protect bone marrow and reduce hematologic adverse events (AEs), as well as improve emerging treatments through myeloprotection which improve patients' overall anti-tumor immune responses combination with the antibody-drug conjugate; and treatment of neoadjuvant breast cancer. In addition, the company develops lerociclib, an oral CDK4/6 inhibitor for multiple oncology indications; and rintodestrant, an oral selective estrogen receptor degrader, and HER2-negative breast cancer. The company has a license agreement with EQRx, Inc. and Genor Biopharma Co. Inc. for the development and commercialization of lerociclib using an oral dosage form to treat any indication in humans, as well as Nanjing Simcere Dongyuan Pharmaceutical Co., LTD. for the development and commercialization of trilaciclib for any indication in humans through parenteral delivery, and ARC Therapeutics for the development and commercialization of a CDK2 inhibitor for all human and veterinary uses. G1 Therapeutics, Inc. was incorporated in 2008 and is headquartered in Research Triangle Park, North Carolina.

GTHX Price History

GTHX Stock News Headlines

This is the #1 Stock to Buy for the AI Tidal Wave
Marc Chaikin warned people about NVDA before its 2023 bull run - now he’s naming his next pick or the AI tidal wave. Learn more here.
G1 Therapeutics earnings: here's what Wall Street expects
Elon Did It Again: This Could be Bigger than Tesla
Love him or hate him, it’s hard to deny Elon Musk is a genius. After revolutionizing online payment processing (PayPal), space exploration (SpaceX), and the auto industry (Tesla)... He’s getting ready to do it again with his new AI venture.
Where G1 Therapeutics Stands With Analysts
BTIG Keeps Their Buy Rating on G1 Therapeutics (GTHX)
BTIG Sticks to Its Buy Rating for G1 Therapeutics (GTHX)
H.C. Wainwright Keeps Their Buy Rating on G1 Therapeutics (GTHX)
See More Headlines
Receive GTHX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for G1 Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

GTHX Company Calendar

Last Earnings
8/02/2023
Today
10/04/2023
Next Earnings (Estimated)
11/01/2023
Fiscal Year End
12/31/2023

Industry, Sector and Symbol

Industry
Pharmaceutical preparations
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:GTHX
Employees
170
Year Founded
N/A

Price Target and Rating

Average Stock Price Forecast
$11.80
High Stock Price Forecast
$19.00
Low Stock Price Forecast
$5.00
Forecasted Upside/Downside
+836.5%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.83
Research Coverage
6 Analysts

Profitability

Net Income
$-147,560,000.00
Pretax Margin
-83.89%

Debt

Sales & Book Value

Annual Sales
$51.30 million
Book Value
$1.60 per share

Miscellaneous

Free Float
47,487,000
Market Cap
$65.21 million
Optionable
Optionable
Beta
1.87
(Almost) Everything You Need To Know About The EV Market Cover

Click the link below and we'll send you MarketBeat's guide to investing in electric vehicle technologies (EV) and which EV stocks show the most promise.

Get This Free Report

Key Executives

  • Mr. John E. Bailey Jr. (Age 58)
    CEO, Pres & Director
    Comp: $1.06M
  • Dr. Mark A. Velleca M.D. (Age 59)
    Ph.D., Sr. Advisor & Director
    Comp: $245k
  • Mr. Mark Avagliano (Age 47)
    Chief Bus. Officer
    Comp: $628.54k
  • Mr. John W. Umstead V (Age 38)
    Chief Financial Officer
  • Mr. Terry L. Murdock (Age 63)
    Chief Operating Officer
  • Mr. William C. Roberts (Age 54)
    VP of Investor Relations & Corp. Communications
  • Mr. Alexander D. Smith M.S.
    VP of Technical Operations
  • Ms. Monica R. Thomas
    Gen. Counsel & Chief Compliance Officer
  • Dr. Jay C. Strum Ph.D. (Age 59)
    Chief Scientific Officer
  • Mr. Evan Hicks M.B.A.
    VP of Marketing













GTHX Stock - Frequently Asked Questions

Should I buy or sell G1 Therapeutics stock right now?

6 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for G1 Therapeutics in the last twelve months. There are currently 1 hold rating and 5 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "moderate buy" GTHX shares.
View GTHX analyst ratings
or view top-rated stocks.

What is G1 Therapeutics' stock price forecast for 2023?

6 analysts have issued twelve-month price targets for G1 Therapeutics' stock. Their GTHX share price forecasts range from $5.00 to $19.00. On average, they anticipate the company's share price to reach $11.80 in the next twelve months. This suggests a possible upside of 836.5% from the stock's current price.
View analysts price targets for GTHX
or view top-rated stocks among Wall Street analysts.

How have GTHX shares performed in 2023?

G1 Therapeutics' stock was trading at $5.43 on January 1st, 2023. Since then, GTHX shares have decreased by 76.8% and is now trading at $1.26.
View the best growth stocks for 2023 here
.

When is G1 Therapeutics' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Wednesday, November 1st 2023.
View our GTHX earnings forecast
.

How were G1 Therapeutics' earnings last quarter?

G1 Therapeutics, Inc. (NASDAQ:GTHX) announced its quarterly earnings results on Wednesday, August, 2nd. The company reported $0.14 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.17) by $0.31. The firm had revenue of $42.39 million for the quarter, compared to analysts' expectations of $28.34 million. G1 Therapeutics had a negative net margin of 87.26% and a negative trailing twelve-month return on equity of 143.26%.

What other stocks do shareholders of G1 Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other G1 Therapeutics investors own include Dynavax Technologies (DVAX), Sorrento Therapeutics (SRNE), ImmunoGen (IMGN), Inovio Pharmaceuticals (INO), Johnson & Johnson (JNJ), Gilead Sciences (GILD), Kadmon (KDMN), VBI Vaccines (VBIV), Novavax (NVAX) and Pfizer (PFE).

When did G1 Therapeutics IPO?

(GTHX) raised $101 million in an initial public offering on Wednesday, May 17th 2017. The company issued 6,300,000 shares at $15.00-$17.00 per share. J.P. Morgan and Cowen and Company served as the underwriters for the IPO and Needham & Company and Wedbush PacGrow were co-managers.

What is G1 Therapeutics' stock symbol?

G1 Therapeutics trades on the NASDAQ under the ticker symbol "GTHX."

How do I buy shares of G1 Therapeutics?

Shares of GTHX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is G1 Therapeutics' stock price today?

One share of GTHX stock can currently be purchased for approximately $1.26.

How much money does G1 Therapeutics make?

G1 Therapeutics (NASDAQ:GTHX) has a market capitalization of $65.21 million and generates $51.30 million in revenue each year. The company earns $-147,560,000.00 in net income (profit) each year or ($1.71) on an earnings per share basis.

How many employees does G1 Therapeutics have?

The company employs 170 workers across the globe.

How can I contact G1 Therapeutics?

G1 Therapeutics' mailing address is 700 Park Offices Drive Suite 200, Research Triangle Park NC, 27709. The official website for the company is www.g1therapeutics.com. The company can be reached via phone at (919) 213-9835, via email at jmacdonald@g1therapeutics.com, or via fax at 919-741-5830.

This page (NASDAQ:GTHX) was last updated on 10/4/2023 by MarketBeat.com Staff

My Account -